140 related articles for article (PubMed ID: 29316585)
1. [Malignant B-Cell Lymphoma: Advances in the Therapy of Follicular Lymphoma and Mantle-cell Lymphoma].
Buske C; Dreyling M
Dtsch Med Wochenschr; 2018 Jan; 143(1):46-51. PubMed ID: 29316585
[No Abstract] [Full Text] [Related]
2. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
4. Highlights from the Pan Pacific Lymphoma Conference. August 15–19, 2011, Kauai, Hawaii.
Cheson BD
Clin Adv Hematol Oncol; 2011 Oct; 9(10 Suppl 24):1-24. PubMed ID: 22362224
[No Abstract] [Full Text] [Related]
5. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
6. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma.
Cencini E; Fabbri A; Schiattone L; Bartalucci G; Bocchia M
Leuk Lymphoma; 2015; 56(10):2997-8. PubMed ID: 25721753
[No Abstract] [Full Text] [Related]
8. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
10. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M
Ann Hematol; 2013 Nov; 92(11):1503-11. PubMed ID: 23737092
[TBL] [Abstract][Full Text] [Related]
11. Stage I-II follicular lymphoma: an endangered species?
McLaughlin P; Seymour JF
Leuk Lymphoma; 2015; 56(8):2229-30. PubMed ID: 26397239
[No Abstract] [Full Text] [Related]
12. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
[TBL] [Abstract][Full Text] [Related]
14. Factors predictive for response of follicular and mantle-cell lymphoma to rituximab.
Pfreundschuh M
Nat Clin Pract Oncol; 2006 Apr; 3(4):184-5. PubMed ID: 16596141
[No Abstract] [Full Text] [Related]
15. Maintenance rituximab in mantle-cell lymphoma.
Burki TK
Lancet Oncol; 2017 Nov; 18(11):e647. PubMed ID: 28988912
[No Abstract] [Full Text] [Related]
16. [Malignant lymphoma in adults].
Fridrik MA
Dtsch Med Wochenschr; 2008 Oct; 133(41):2109-14. PubMed ID: 18985565
[No Abstract] [Full Text] [Related]
17. [Hematopoietic stem cell transplantation for malignant lymphoma].
Asaoku H
Nihon Rinsho; 2000 Mar; 58(3):704-8. PubMed ID: 10741150
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas.
Nabhan C; Ollberding NJ; Villines D; Chiu BC; Caces DB; Valdez TV; Ghielmini M; Hsu Schmitz SF; Smith SM
Leuk Lymphoma; 2014 Jun; 55(6):1288-94. PubMed ID: 23998254
[TBL] [Abstract][Full Text] [Related]
20. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
